CTOs on the Move

Medical Practice Management Services

www.medpracmgmt.com

 
Medical Practice Management Services is a Coeur D Alene, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medpracmgmt.com
  • 700 W Ironwood Dr Ste 272e
    Coeur D Alene, ID USA 83814
  • Phone: 800.215.6224

Executives

Name Title Contact Details

Similar Companies

Nunn'S Hospital Supplies Inc

Nunn'S Hospital Supplies Inc is a Rome, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardinal Center Inc

Cardinal Center Inc is a Warsaw, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeuroSigma, Inc.

NeuroSigma is a Los Angeles-based life sciences company established to develop TNS technologies with the potential to transform medical practice and patients' lives.  NeuroSigma is focused on TNS neuromodulation therapies based on intellectual property licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including TNS therapies for epilepsy, depression, post-traumatic stress disorder (PTSD) and attention-deficit hyperactivity disorder (ADHD).

The Roberts Group

The Roberts Group, Inc. is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.